Drugs / Myrcene
last change Jul 2026 re-read 2 minutes ago

Myrcene

Small molecule

Developed for
dysmenorrhea · migraine disorder · mood disorder
Investigated by
Johns Hopkins University · National Institute on Drug Abuse (NIDA) · Pure Green

Trials 2 · a red edge is where a trial was stopped

202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05432284 Jul 2026 → Nov 2027 expected substance-related disorder Johns Hopkins University Not yet recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT04091789 Sep 2019 → Mar 2020 dysmenorrhea, migraine disorder, mood disorder Pure Green Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04451863 Comparator Dec 2021 → Nov 2025 overdue substance abuse University of California, Los Angeles Active not recruiting No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as myrcene “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789
1

NCT04451863

Known as .beta.-geraniolene ChEMBL registry synonym — accepted as the source's own label CHEMBL455491
Known as Beta-Myrcene ClinicalTrials.gov intervention name — accepted as the source's own label NCT05432284
Known as FEMA NO. 2762 ChEMBL registry synonym — accepted as the source's own label CHEMBL455491
Known as NSC-406264 ChEMBL registry synonym — accepted as the source's own label CHEMBL455491
Modality Small molecule CHEMBL455491
Route Other “A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene,...” NCT04091789